TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04193982
Drug: Combination drug
Normalized name: combination drugs used in erectile dysfunction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient receives Vitamine E 400mg twice daily and Saraglitazar 4 mg once daily for 6 months
Study: NCT06215716
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT06317051
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo tablets are visually identical to the active drug tablets and will be administered as a comparator to Dapagliflozin.
Study: NCT05139316
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who receive DTX401 solution will receive oral corticosteroids
Study: NCT05139316
Drug: Placebo for oral corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who receive Placebo will receive placebo oral corticosteroids to maintain the study blind
Study: NCT05593328
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI (irinotecan + fluorouracil \[5-FU\] + leucovorin) as intravenous (IV) infusion
Study: NCT06223659
Drug: Eutectic Mixture of Local Anesthetics
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply topically to skin
Study: NCT05503043
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are received equal volumes of saline intravenously until the end of the surgery
Study: NCT04898023
Drug: zinc-green tea extract-ascorbic acid
Normalized name: green tea extract
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compounded capsules containing each zinc citrate, green tea extract, and ascorbic acid.
Study: NCT04945460
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT05814016
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching danavorexton IV infusion.
Study: NCT04957485
Drug: Smallpox and Mpox Vaccine
Normalized name: smallpox and mpox vaccine, live, nonreplicating
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaccine
Study: NCT05804279
Drug: BPDO-1603
Approvals — FDA: no, EMA: no, PMDA: no
Description: donepezil/mematine
Study: NCT05587361
Drug: Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Patch, no active ingredients
Study: NCT05792540
Drug: Fluoxetine 20 mg
Normalized name: fluoxetine 20 MG
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine is a type of antidepressant known as a selective serotonin reuptake inhibitor (SSRI). It's often used to treat depression, and sometimes obsessive-compulsive disorder and bulimia. It works by increasing the levels of serotonin in the brain
Study: NCT04915365
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral capsules, identically looking as active drug), starting dose 3 capsules, subsequent doses~1 capsule in the morning, 2 capsules in the evening, administered in qualifying participants, during the stay at 3100 m.
Study: NCT05949801
Drug: Neucardin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days IV infusion of 0.6 ug/kg/day
Study: NCT05949801
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days IV infusion of 0 ug/kg/day
Study: NCT05534165
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical placebo 600 mg po BID
Study: NCT06075771
Drug: Carbidopa Levodopa
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive between one and three tablets per day of 150 mg L-DOPA (administered with 37.5 mg carbidopa) to achieve doses ranging from 150 to 450 mg/day.
Study: NCT06075771
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive between one and three placebo tablets per day matching the Carbidopa Levodopa tablet.
Study: NCT00367822
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06750341
Drug: QLC7401
Approvals — FDA: no, EMA: no, PMDA: no
Description: QLC7401 combined with lipid-lowering agents
Study: NCT06750341
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo combined with lipid-lowering agents
Study: NCT04791228
Drug: Lyso-thermosensitive Liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTLD combines doxorubicin with lyso-thermosensitive liposomes that can selectively deliver drug to tumors and when exposed to temperatures greater than 40°C, rapidly and locally releases doxorubicin in high concentrations from systemically administered LTLD.~If combined with hyperthermia, doxorubicin will be released in the heated tumor margins and in any areas within the tumor that were not completely ablated and increase the likelihood of complete tumor necrosis. LTLD will extend tumor cell death to the hyperthermic regions in the peri-ablation zones and minimize the possibility of incomplete ablation or tumor recurrence.
Study: NCT05442827
Drug: SHR7280 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR7280 tablets 300mg for 12 weeks
Study: NCT05442827
Drug: SHR7280 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR7280 tablets 400mg for 12 weeks
Study: NCT05442827
Drug: PlaceboSHR7280 tablets blank preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group: SHR7280 tablets blank preparation for 12 weeks
Study: NCT04593784
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: 0.9% sodium chloride, intravenous
Study: NCT06137027
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered sublingually 2-3 hours preoperatively
Study: NCT06135298
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZA), is a bisphosphonate, and has been shown to reduce the risk of hip fracture by 41% in post-menopausal women. For systemic injection, 5 mg (as per clinical protocol) will be injected intravenously 5 days after surgery, during hospitalization.
Study: NCT06286189
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule taken 30 min before sleep
Study: NCT04576988
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously (SC) every 21 days plus background PAH therapy.
Study: NCT04576988
Drug: Background PAH Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Background PAH therapy may consist of the following drug classes: an endothelin-receptor antagonist (ERA), a phosphodiesterase 5 (PDE5) inhibitor, a soluble guanylate cyclase stimulator, and/or a prostacyclin analogue or receptor agonist.
Study: NCT06434610
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: The subjects will receive IV dose of placebo matched to B013 on Day 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.
Study: NCT04408989
Drug: MB02-SP
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion
Study: NCT04408989
Drug: US licenced Avastin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion
Study: NCT04246151
Drug: Probiotic Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar pill manufactured to mimic 10 billion unit probiotic capsules.
Study: NCT05488678
Drug: VNRX-7145
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose
Study: NCT06225011
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Receive PO
Study: NCT06376201
Drug: Amphotericin B cholesterol-sulfate complex for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were eligible for enrollment on antifungal therapy with injectable amphotericin B cholesterol-sulfate complex (ABCD) at the same time as a treatment for underlying disease.~Dosage: According to the patient's condition and the investigator's judgment, the initial dose of ABCD can be 0.5-1.0mg/kg/d, and the dose can be increased daily according to the situation, and the therapeutic dose can be increased to 3.0-4.0mg/kg/d on the third day.~Course of treatment: ≥ 14 days (whether to continue to receive trial drug treatment after 14 days is decided by the investigator according to the patient's condition).
Study: NCT06026527
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml Normal Saline will be infused intravenously over 20-30 minutes in the participants allocated to control group starting from the moment of induction of anaesthesia
Study: NCT06752746
Drug: 9MW3011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose
Study: NCT05631574
Drug: BMF-219
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.
Study: NCT04703101
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04703101
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04703101
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06118281
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to ziltivekimab will be adminsitered subcutaneously as an initial loading dose followed by a maintenance dose once-monthly.
Study: NCT06775782
Drug: Medical Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive standard guideline-directed medical therapy, which will include monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic therapy if appropriate.
Study: NCT04836559
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally.
Study: NCT04995523
Drug: AZD2936
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TIGIT/Anti-PD-1 Bispecific Antibody
Study: NCT05375461
Drug: TQB3616 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of TQB3616 capsules is 180mg, taken orally on an empty stomach, once a day for 28 consecutive days as one treatment cycle.
Study: NCT05375461
Drug: TQB3616-matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of placebo is 180mg, taken orally on an empty stomach, once a day for 28 consecutive days as one treatment cycle.
Study: NCT05375461
Drug: Fluvestrin injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvestrin injection was given at a fixed dose of 500mg on day 1, day 15 of the first treatment cycle and day 1 of each subsequent treatment cycle, and a treatment cycle of 28 days.
Study: NCT06022029
Drug: ONM-501
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratumoral injection
Study: NCT06780410
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, oral
Study: NCT06157216
Drug: MRD-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRD negative stage II gastric cancer: Observation; MRD negative stage III gastric cancer: S1 (40-60 mg, PO, bid, d1-d14 q3w); MRD positive stage II/III gastric cancer: XELOX (Oxaliplatin 130mg/m2, d1 +Capecitabine 1000mg/m2，PO. bid, d1-14, q3w) or SOX (Oxaliplatin 130mg/m2, d1 +S-1 40-60 mg, PO. bid, d1-14, q3w); MRD-negative patients will receive XELOX or SOX if MRD becomes positive.
Study: NCT06504160
Drug: ShA9 Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: The ShA9 topical gel contains phosphate-buffered saline solution (PBS), Glycerol, and hydroxyethylcellulose containing lyophilized ShA9 bacteria. The ShA9 bacteria is derived from a healthy donor-derived (allogeneic) commensal Staph species. The gel is manufactured and packaged by University of California San Diego (UCSD). It is applied twice daily to all areas identified as actively lesional during the Baseline Visit, regardless of ongoing lesional status, until the Week 14 Visit. If new lesions arise during this time, these areas will also be treated, regardless of ongoing lesional status, until the Week 14 Visit.
Study: NCT06504160
Drug: Hydrocortisone Ointment
Normalized name: Hydrocortisone Ointment
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All participants will apply hydrocortisone ointment 2.5% alongside the study product in sensitive body areas (e.g., face, neck, intertriginous regions) for the first two weeks of the trial. It is applied twice daily to all areas identified as actively lesional during the Baseline Visit, regardless of ongoing lesional status, until the Week 2 Visit. If new lesions arise during this time, these areas will also be treated, regardless of ongoing lesional status, until the Week 2 Visit.
Study: NCT06504160
Drug: Placebo (Vehicle) Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo (vehicle) topical gel contains phosphate-buffered saline solution (PBS), Glycerol, and hydroxyethylcellulose. The gel is manufactured and packaged by University of California San Diego (UCSD). It is applied twice daily to all areas identified as actively lesional during the Baseline Visit, regardless of ongoing lesional status, until the Week 14 Visit. If new lesions arise during this time, these areas will also be treated, regardless of ongoing lesional status, until the Week 14 Visit.
Study: NCT05607446
Drug: TQC3564 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQC3564 tablets are CRTH2 antagonists.
Study: NCT05607446
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention drug is placebo.
Study: NCT05038306
Drug: Chinese medicine WT
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Chinese medicine WT is thought to be neurotrophic, and its major constituent may benefit IGF-1 in animal studies, or certain healthy human group. WT is safe in clinical use in Asia.
Study: NCT04643158
Drug: AZD1402
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomised participants will receive oral inhalation of AZD1402, via DPI.
Study: NCT04643158
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomised participants will receive oral inhalation of matching placebo via DPI.
Study: NCT04643158
Drug: Short acting beta agonist (SABA) (rescue medication)
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: In addition to study intervention, all participants will be provided with a SABA as rescue medication (eg, salbutamol/albuterol), to be used throughout the Run-in and Treatment Periods. All participants should refrain from taking a SABA as rescue medication 6 hours prior to pulmonary function tests.~Dosage levels: 100 μg per nominal dose 90 μg per nominal dose pro re nata (as required) (PRN)
Study: NCT06182839
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will get 1 pill of placebo daily for one year.
Study: NCT06764836
Drug: IMM27M
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection
Study: NCT06764836
Drug: IMM2510
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection
Study: NCT04934722
Drug: Androgen Deprivation Therapy (ADT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable regimen of ADT (LHRH agonist or antagonist) at a dose and frequency of administration that is consistent with the local product label.
Study: NCT05064449
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefenamic acid capsule.
Study: NCT05994690
Drug: Standard Intervention Rc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 consolidation courses (HAM + HA3E + FLA)
Study: NCT05994690
Drug: Investigational Intervention Ri
Normalized name: Ri-Mag Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of GO to first induction course
Study: NCT05751850
Drug: HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR070803 in combination with oxaliplatin, 5-fluorouracil, calcium folinate
Study: NCT06021912
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy
Study: NCT05546515
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be prescribed up to 30 days of placebo medication.
Study: NCT05917938
Drug: NNC0194-0499
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0194-0499 will be administered subcutaneously in a skinfold in the thigh in the form of a solution for injection.
Study: NCT05304468
Drug: induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: cisplatin-based induction chemotherapy for two cycles
Study: NCT06368440
Drug: AZD6793
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive AZD6793 multiple doses daily as oral suspension.
Study: NCT06368440
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching doses of placebo as oral suspension.
Study: NCT06614881
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: loading dose of saline was injected 10-min before induction of anesthesia.
Study: NCT05845424
Drug: Guideline directed statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: At least moderate intensity statin, recommended by the current guideline based on the ASCVD risk
Study: NCT05215847
Drug: ARD-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily, oral administration
Study: NCT05370495
Drug: SY-201 Ophthalmic Solution 2.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY-201 Ophthalmic Solution 2.0%
Study: NCT05370495
Drug: SY-201 Ophthalmic Solution 1.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY-201 Ophthalmic Solution 1.0%
Study: NCT05370495
Drug: SY-201 Ophthalmic Solution 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY-201 Ophthalmic Solution 0.5%
Study: NCT04231708
Drug: Yohimbine + Hydrocortisone
Normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (54mg bulk powder inside capsule) administered in combination with Hydrocortisone (20mg tablet inside capsule)
Study: NCT04231708
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: lactose (inside capsule)
Study: NCT06009653
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo subcutaneous injections.
Study: NCT06541574
Drug: Methotrexate Injection
Normalized name: methotrexate Injection
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate injection
Study: NCT05453552
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3,-2.
Study: NCT06541574
Drug: Methotrexate Infusion
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate Infusion
Study: NCT05134012
Drug: [O-15]-Water PET Myocardial Perfusion Imaging (MPI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[15-O\]-H2O injection is a novel PET imaging agent labeled with the radioisotope \[15-O\] administered as an intravenous (IV) injection. Participants will receive \[15-O\]-H2O treatment twice as a part of a single day imaging session. All participants will receive two IV boluses of \[15-O\]-H2O injection in a peripheral vein; one at rest and one during pharmacological stress.
Study: NCT06587698
Drug: BeiDouGen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg BID for 3 month
Study: NCT05279755
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral solution
Study: NCT06589752
Drug: TARPEYO 4 MG Delayed Release Oral Capsule
Normalized name: Tarpeyo 4 MG Delayed Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: TARPEYO dispensing claim for any dose is exposure
Study: NCT06589752
Drug: RAS inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: RASi dispensing claim for any dose is reference
Study: NCT06272487
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered by SC injection
Study: NCT04409080
Drug: REGN7257
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by intravenous (IV) infusion, in Part A and B.
Study: NCT05945537
Drug: INI-822 (A)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different dose levels of INI-822
Study: NCT05724134
Drug: Growth Hormone, Human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant human growth hormone (rhGH) will be replaced at a constant rate of up to 3 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and glucagon.
Study: NCT05809271
Drug: MDMA 120 mg + placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An oral dose of 120 mg racemic MDMA will be administered followed by a placebo two hours later.
Study: NCT05809271
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An oral placebo will be administered followed by a placebo two hours later.
Study: NCT06744504
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: combined with cytarabine and idarubicin and used for post-remission treatment
Study: NCT05175352
Drug: CYP substrates
Normalized name: estradiol cypionate / testosterone cypionate Injectable Solution [Duo-Cyp]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05601219
Drug: ADA-011
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADA-011 will be administered intravenously (IV) Q3W on a 21-day cycle.
Study: NCT05601219
Drug: PD(L)-1 inhibitor
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD(L)-1 inhibitor will be administered intravenously (IV) Q3W.
Study: NCT05142722
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet made to resemble active
Study: NCT05687903
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablets matching TAK-861
Study: NCT06614907
Drug: QL2108 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg/2.0mL; single dose; prefilled syringe; subcutaneous injection
Study: NCT06614907
Drug: Dupixent®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg/2.0mL; single dose; prefilled syringe; subcutaneous injection